Haleon (NYSE:HLN) Cut to Equal Weight at Barclays

Key Points

• Haleon has been downgraded by Barclays from an "overweight" rating to an "equal weight" rating, indicating a change in market sentiment toward the stock.
• Despite the downgrade, Haleon still has two analysts rating it as Strong Buy, three as Buy, and five as Hold, reflecting a diverse range of opinions on its potential.
• The company has a market cap of $43.35 billion with recent trading figures showing shares opened at $9.69 and have a one-year high of $11.42.

Haleon (NYSE:HLN - Get Free Report) was downgraded by analysts at Barclays from an "overweight" rating to an "equal weight" rating in a research report issued on Tuesday, Marketbeat Ratings reports.

Other analysts have also recently issued reports about the company. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. The Goldman Sachs Group raised Haleon from a "neutral" rating to a "buy" rating in a research report on Wednesday, September 10th. Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research report on Tuesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Haleon currently has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Trading Down 0.9%

Shares of NYSE HLN traded down $0.08 during trading hours on Tuesday, hitting $9.16. The company's stock had a trading volume of 9,669,121 shares, compared to its average volume of 8,591,749. The stock has a market cap of $41.00 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.73 and a beta of 0.24. Haleon has a 12 month low of $8.86 and a 12 month high of $11.42. The business has a 50-day simple moving average of $9.66 and a 200-day simple moving average of $10.17. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Haleon by 6.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company's stock valued at $306,000 after acquiring an additional 1,749 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Haleon during the first quarter valued at approximately $1,767,000. Oppenheimer & Co. Inc. raised its stake in shares of Haleon by 11.2% during the first quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company's stock valued at $261,000 after acquiring an additional 2,564 shares in the last quarter. Concurrent Investment Advisors LLC raised its stake in shares of Haleon by 32.9% during the first quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company's stock valued at $168,000 after acquiring an additional 4,055 shares in the last quarter. Finally, Mather Group LLC. raised its stake in shares of Haleon by 60.7% during the first quarter. Mather Group LLC. now owns 9,036 shares of the company's stock valued at $93,000 after acquiring an additional 3,413 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.